A cardboard shipping box on a medspa counter with a peeling sticker that reads "For Research Use Only, Not for Human Consumption."

“Research Use Only” Is Not a Loophole. Where Peptides Stand Right Now.

Compounded Drugs| Legal Compliance
October 05, 2026

By Kate Dee, MD — Founder, MedSpa Board

On August 24, 2026, the FDA sent warning letters to five online peptide sellers: Peak Performance Peptides, NuScience Peptides LLC, Royal Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC, which does business as Tex Peptides. All five were selling injectable peptides, including semaglutide, tirzepatide, retatrutide, tesamorelin, and PT-141, under a label that said some version of “for research use only.”

The FDA’s answer, in each letter, was that the label does not matter. These are unapproved new drugs being sold for human use.

That is the federal half of the story. The other half is happening at the state level, and it is aimed squarely at licensed providers. Since May, licensing boards in Alabama and Mississippi have told their licensees, in nearly identical words, that there are no circumstances under which they may give a research-grade peptide to a patient. South Carolina’s medical board is reported to have done the same. Ohio’s pharmacy board has been suspending medspa licenses over it.

Research-use-only peptides are everywhere in this industry. They are in medspa refrigerators, on wellness clinic menus, and in the gym bags of patients who ask their injector for “advice” on dosing. Plenty of licensed physicians, NPs, and PAs have convinced themselves this is a gray area. It is not, and regulators have now said so in writing.

A note on sourcing. What follows comes from the FDA’s letters, the boards’ own published statements where I could obtain them, and law firm reporting where I could not. I have marked which is which. A warning letter records the FDA’s findings. It is not a court judgment, and the companies have the opportunity to respond.

What the FDA said to the five sellers

The letters cite sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act: introducing unapproved new drugs into interstate commerce. Each company has 15 business days to respond, and each letter warns that failure to correct the violations may result in seizure and injunction.

What matters is how the FDA got past the disclaimer. Under federal law, a product is a drug if it is intended to affect the structure or function of the body or to treat disease. Intent is judged by everything the seller says and does, not by one disclaimer on the vial.

Peak Performance Peptides, of Phoenix, labeled its products “for research use only” and “not for human consumption.” Its website also described its retatrutide product as “studied for its potential effects on metabolic regulation, body weight management,” and its semaglutide as studied for “glucose regulation, appetite control.” It sold bacteriostatic water for reconstituting them.

NuScience Peptides, of Cornelius, North Carolina, labeled its products “for laboratory, research, and analytical use.” The FDA wrote: “you market bacteriostatic water alongside a peptide calculator, a resource that provides the means to prepare an injectable drug for human administration.”

No laboratory needs a dosing calculator and a vial of bacteriostatic water to run an assay. Those are the supplies a person needs to inject himself or others. According to a summary of the five letters by the law firm ArentFox Schiff, the FDA pointed to the same kinds of evidence across the group: disease and weight loss claims, dosing guidance, reconstitution calculators, and bacteriostatic water sold alongside the vials.

This is not new. The FDA sent a similar round of letters to online peptide sellers in December 2024. And readers of this blog will remember our piece on Paradigm Peptides, whose owner received FDA warning letters in 2020 and 2022, kept selling, and was sentenced on July 30, 2026 to 70 months in federal prison. A warning letter is where these cases start.

What state boards are telling licensed providers

Alabama went first. On May 26, 2026, the Alabama Board of Medical Examiners and Medical Licensure Commission issued an official notice that reads: “under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient.” The notice extends the prohibition to advising, recommending, supplying, and prescribing. It also closes the delegation door: a physician may not hand the task to a certified nurse midwife, a nurse practitioner, or a PA, because those providers may prescribe only from Board-approved formularies and research-grade peptides are on none of them. Physicians must buy every prescription product from an entity permitted by the Alabama State Board of Pharmacy.

Mississippi followed on August 19, 2026, and it was not only the medical board. The Mississippi State Board of Medical Licensure, the Board of Nursing, and the Board of Pharmacy signed a joint statement: “Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non-FDA approved or research-grade peptide to a patient.” That covers physicians, nurse practitioners, PAs, nurses, and pharmacists alike.

The Mississippi statement also takes apart the industry’s favorite defense. “Patient consent forms purporting to identify a product as ‘research-grade’ do not mitigate or eliminate a provider’s professional or legal liability.” A waiver does not work. A patient cannot sign away your duty of care.

South Carolina’s Board of Medical Examiners issued a similar statement in mid-August 2026, according to an analysis by Lumalex Law. As reported, it bars physicians from delegating these activities to nurse practitioners and PAs, states that consent does not eliminate liability, and specifically flags semaglutide salt forms and research-grade powders. I have not been able to obtain the board’s own document, so I am attributing this one to the firm’s reporting.

Ohio has moved past statements. The Ohio Board of Pharmacy publishes a list titled “Ten Common Prescriber Clinic and Medical Spa Violations,” updated December 8, 2025. Violation number one is purchasing drugs from unlicensed sellers, including sellers on social media. Number two is possessing medications labeled “for research purposes only,” and it names retatrutide and cagrilintide. The list also calls out BPC-157. The law firm Frier Levitt reported in August 2025 that four Ohio medspa licenses had been suspended after complaints and reports of adverse patient outcomes tied to unapproved peptides. Sheppard Mullin reported that in February 2026 the Board summarily suspended more than thirty clinics and medical spas.

None of these boards passed a new law. They restated duties that already existed under every state’s medical practice act and pharmacy law. That means a provider in a state that has not issued a statement is not in the clear. Your board simply has not put it in a press release yet.

The boards do draw one line. An adult who buys a vial online and injects himself, with no licensed provider involved, carries that risk alone. The moment a licensee advises on dosing, supplies the product, or pushes the plunger, the licensee owns the outcome.

“But the FDA is legalizing peptides”

This is the confusion I hear most, so here is the status as of today.

In April 2026, the FDA removed twelve peptides from Category 2 of its 503A bulk substances list, the category for substances that raise significant safety concerns. On July 23 and 24, its Pharmacy Compounding Advisory Committee voted on seven of them. It recommended six for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. The votes were close, 8 to 6 with one abstention for BPC-157, and the FDA’s own reviewers had argued against inclusion. The committee voted against the seventh, emideltide, also called DSIP.

That vote deserves a closer look, because the committee that cast it has been heavily criticized. Eight of its members were newly appointed on June 29, 2026, less than four weeks before the meeting. STAT reported that, according to FDA officials, the Department of Health and Human Services selected many of the panelists, and that FDA staff were among those raising conflict-of-interest questions.

TIME reported that “many of the voting members on the committee consult with or are employed by companies that could promote or dispense peptides.” One voting member, Dr. Haleem Mohammed, is the chief medical officer of Gameday Men’s Health; TIME reports he voted yes on BPC-157 and KPV. Another, Bobby Harshbarger, is a Tennessee state senator whose mother, U.S. Rep. Diana Harshbarger, has publicly advocated for looser peptide regulation. According to TIME, members who represent or advise telehealth companies cast most of the yes votes. Fierce Pharma reported that the FDA added eight temporary voting members the week of the meeting in response to the conflict criticism.

The objections came from inside the room as well. Committee member Dr. Elizabeth Rebello of MD Anderson Cancer Center said, “I’m concerned that we’re responding to a market-induced demand rather than a decision based in solid science.” Nina Zeldes of Public Citizen’s Health Research Group told the committee that interest in these substances “appears to be driven by those who stand to benefit from increased demand.” Critics describe the panel as stacked with people who profit from peptides. Whatever you call it, “an FDA committee voted for it” is weak evidence that these drugs are safe, and it is no evidence at all that they work.

A committee recommendation is advisory. None of the six has been added to the list. That requires formal rulemaking, which the law firm McDermott Will & Schulte expects could run into 2027 or later.

More important, that entire process is about compounding: a licensed pharmacy preparing a drug from pharmaceutical-grade ingredients for an identified patient with a valid prescription. It has nothing to do with a vial from a website that says “not for human consumption.” If BPC-157 lands on the bulks list tomorrow, the research-use-only vial is still an unapproved drug.

Retatrutide deserves its own sentence. It is an investigational Eli Lilly drug that has not been approved by the FDA. There is no lawful way to buy it, compound it, or administer it outside a clinical trial. Lilly sued six businesses in federal court in Texas on August 12, 2026, including four research-use-only sellers, a compounding pharmacy, and a medspa, and says it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, and professional licensing boards. If retatrutide is on your menu, your name may already be on someone’s list. It is simply not legal to buy or prescribe retatrutide at this time in any way, shape, or form.

This is not only the sellers

It would be comfortable to treat this as a story about sketchy websites. But those websites have customers, and a great many of them hold licenses.

Medspas and wellness clinics buy these vials because they cost a fraction of what a legitimate product costs. Some reconstitute them in a back room and inject them. Some sell them at the front desk. Some have an RN or an aesthetician handing them out under a “protocol” signed by a medical director who has never seen the patient. Each of those is a separate violation. The product is an unapproved drug. Mixing it outside compounding standards is a pharmacy violation. An RN or aesthetician cannot prescribe anything in any state, and a prescriber who signs for patients he or she never assessed is not practicing medicine either.

The legitimate practices in this industry get lumped in with all of it. Every news story about a “peptide clinic” makes patients trust medspas a little less, including the ones doing it right.

What legal compliance looks like

Know the three categories. An FDA-approved peptide drug, prescribed for a patient by someone with authority to prescribe, is legal. A peptide compounded by a licensed pharmacy, for an identified patient, under a valid prescription, from a bulk substance that qualifies under federal law, may be legal, and you need to confirm that for each substance. A research-use-only vial is never legal to give to a patient.

Read the label. If it says “research use only,” “not for human consumption,” or “for laboratory use,” it does not belong in a medical practice. Remove it from inventory today.

Check your supplier’s license. Every prescription product should come from a pharmacy, wholesaler, or manufacturer licensed in your state. Most boards of pharmacy have a public lookup. A website with a shopping cart and a certificate of analysis is not a licensed supplier.

Confirm who is prescribing. The order must come from a physician, or from an NP or PA acting within their scope and any required supervision or collaboration, after a real evaluation of that patient.

Throw out the waiver. Two state boards have now said in writing that a consent form calling the product research-grade does nothing for you.

Do not coach from the sidelines. “I can’t sell it to you, but here is how I would dose it” is advising and recommending. Alabama and Mississippi both prohibit exactly that.

Audit your website and social media. If your menu lists BPC-157, TB-500, or retatrutide, a regulator can read it as easily as a patient can.

What patients should know about peptides

If a provider is recommending a peptide, these are the questions you have to ask: Is this drug FDA-approved? If not, which pharmacy compounded it, and is my name on the label? Can I see the vial? Does it say “research use only” anywhere? Who prescribed it, and did that person examine me? Look up the prescriber’s license. Look up the medical director’s too. If the answers are vague, leave.

And a word to the many people who order these vials on purpose to inject themselves: do not do it. The state boards have said that when no licensed provider is involved, the risk is yours alone. It is a bigger risk than the websites let on, and it comes from three directions.

The first is the peptide itself. Most of these compounds have never been through a controlled human trial. FDA scientists told the advisory committee there was minimal evidence that they are safe or effective, and raised concerns about serious harms, including cancer and bleeding. Nobody knows the right dose, because nobody has established one.

The second is contamination. A drug made for injection must be sterile and tested for endotoxin, the bacterial debris that can cause fever, a dangerous drop in blood pressure, and shock even when no live bacteria are left. A research chemical has to meet neither standard. A certificate that says "99% pure" describes the peptide. It says nothing about bacteria or endotoxin. Then the powder gets mixed on a kitchen counter.

The third is that the vial may contain something else entirely. When the government tested Paradigm Peptides' muscle-building products, they turned out to be testosterone, and the company's lab certificates were forged. As the chair of the Alabama Board of Medical Examiners put it, "there is no reliable way to verify what it actually is, how it was manufactured or what risks it may pose."

If you want one of these drugs, see a licensed prescriber and get a product that is FDA-approved or lawfully compounded for you by a licensed pharmacy.

Where MedSpa Board certification fits

The MedSpa Board cannot stop a website from shipping vials. What certification does is make visible the practices that know what is in the vial, where it came from, who prescribed it, and why.

If you run a medspa and your standards are ready to be verified, begin your application now. If you want to see where you stand first, download our free checklist that tells you all the requirements to become certified.

— Kate Dee, MD

Sources & further reading

research use only peptidesRUO peptidesare peptides legalFDA peptide warning letterspeptide crackdown 2026state medical board peptidesresearch-grade peptidesBPC-157 legal statusretatrutide legalcompounded peptides503A bulk drug substancesmedspa compliancemedspa peptide therapypeptide injection risksMedSpa Board certification
Dr. Kate Dee
Dr. Kate Dee|LinkedIn logo iconInstagram logo iconYoutube logo icon
Dr. Kate Dee is a Yale-educated physician and founder of the Medspa Board. She is passionate about educating people about the benefits of aesthetics treatments while avoiding the risks and shady practices.
Back to Blog

Medspa Board certification helps licensed med spas stand out by building trust, attracting high-quality clients, and showcasing verified credentials. We help consumers identify top quality medspas that emphasize safety and medical excellence.

CONTACT US

© Copyright 2026. The Medspa Board. All Rights Reserved.